| Bid | 5.61 |
| Market Cap | 155.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.04 |
| PE Ratio (ttm) | -142.12 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.72 |
| Volume | 2,725 |
| Avg. Volume (20D) | 122,203 |
| Open | 5.78 |
| Previous Close | 5.64 |
| Day's Range | 5.65 - 5.78 |
| 52-Week Range | 3.96 - 11.49 |
| Beta | undefined |
About FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is ba...
Analyst Forecast
According to 2 analyst ratings, the average rating for FENC stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 146.27% from the latest price.
Next Earnings Release
Analysts project revenue of $12.02M, reflecting a 23.47% YoY growth and earnings per share of -0.03, making a -70.00% decrease YoY.
2 months ago · seekingalpha.com
Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call TranscriptFennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Off...
